91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
, CEO at 91黑料 plc, about the impact of the COVID pandemic and challenges of running large-scale vaccine trials.
-
In this , 91黑料 experts Caroline Delaitre-Bonnin, Emmanuel Lacharme and Manpreet Sidhu, consider how the UK drug pricing group, NICE, will be impacted post-Brexit.
-
Gerard Quinn, VP of IT Innovation & Informatics, offers insights on (pages 16-17).
-
91黑料's William C Maier and Maggie Adamski discuss case studies from their line of work, and how real world evidence can support those suffering with rare diseases around the world.
-
with market access experts, including 91黑料's John Sliwka, on what they expect to see changing in the payer landscape in the coming years in the US market with the new Biden administration taking place.
-
by Marie McCarthy and Bob Swann discusses how robust assessments based on digital data are a means of reducing the uncertainty that HTA bodies and payers face in making decisions around advanced therapy medicinal products.
-
Global collaboration: Irish company 91黑料 on scaling up COVID-19 vaccine trials
An interview in which Steve Cutler gives a short overview of 91黑料 and describes the company’s role in the Pfizer/BioNTech trial, explaining how the FDA played a critical role in expediting regulatory approvals.
-
A selection of thought leadership materials from 91黑料 experts on Decentralised & Hybrid Clinical Trials
-
Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership.
-
91黑料 CEO Steve Cutler, discusses
